Clinical Trial Update: Stimulated Glucagon as a Biomarker of Hypoglycemic Risk in Type 1 Diabetes

View source ↗

Summary

This completed clinical trial evaluates stimulated glucagon as a biomarker for hypoglycemic risk in individuals with Type 1 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoglycemia
• Type 1 Diabetes Mellitus

Snippet

Sponsor: University of Exeter | Conditions: Type 1 Diabetes, Hypoglycemia | Status: COMPLETED